TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34534863

Group type: EXPERIMENTAL
Intervention: Injection extended-release naltrexone (XR-NTX), delivered approximately every 28 days
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Daily sublingual buprenorphine-naloxone (BUP-NX)
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Estimated individualized treatment rule for OUD
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Simpler alternative estimated rule (homeless participants treated with XR-NTX, stably housed participants treated with BUP-NX)
Number of subjects: 570
Study: 36357824

Group type: EXPERIMENTAL
Intervention: Conversation aid intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 32946039

Group type: EXPERIMENTAL
Intervention: Bloodletting puncture at hand twelve Jing-Well points (HTWPs)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Routine Western medicine
Number of subjects: 360
Study: 32487150

Group type: EXPERIMENTAL
Intervention: Magnesium oxide (500 mg thrice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naldemedine (0.2 mg once daily)
Number of subjects: 0
Study: 35488084

Group type: EXPERIMENTAL
Intervention: lenrispodun 1.0 mg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: lenrispodun 10.0 mg
Number of subjects: 26

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: lenrispodun
Number of subjects: 26
Study: 34162218

Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg/d
Number of subjects: 1120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1120

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 1120

Group type: COMPARATOR
Intervention: Pravastatin and Placebo
Number of subjects: 1120
Study: 32784346

Group type: EXPERIMENTAL
Intervention: IV vortioxetine 25 mg plus daily oral vortioxetine 10 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: IV placebo plus daily oral placebo
Number of subjects: 80
Study: 36379827

Group type: EXPERIMENTAL
Intervention: Modified Vocal Function Exercises with reduced requirement for maximally sustained phonation (midpoint group MG)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Vocal Function Exercises (traditional group TG)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Modified Vocal Function Exercises with removed requirement for maximally sustained phonation (baseline group BG)
Number of subjects: 34
Study: 35225388

Group type: EXPERIMENTAL
Intervention: Home solar lighting system at no cost to study participants
Number of subjects: 80
Study: 33185372

Group type: EXPERIMENTAL
Intervention: Percutaneous cervical nucleoplasty (PCN)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Anterior cervical discectomy (ACD)
Number of subjects: 48

Group type: COMPARATOR
Intervention: ACD
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: PCN
Number of subjects: 48
Study: 35393874

Group type: EXPERIMENTAL
Intervention: Diabetes app
Number of subjects: 154

Group type: COMPARATOR
Intervention: Standard diabetes care
Number of subjects: 154
Study: 33648515

Group type: EXPERIMENTAL
Intervention: Empagliflozin (EMPA) 10 mg/day in humans
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Empagliflozin (EMPA) 30 mg/kg in mice
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Empagliflozin (EMPA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 32894959

Group type: EXPERIMENTAL
Intervention: Pectoral nerve block with 30 ml ropivacaine 0.375% (Pecs group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Thoracic paravertebral block with 20 ml ropivacaine 0.5% (TPVB group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pecs group
Number of subjects: 60

Group type: COMPARATOR
Intervention: TPVB group
Number of subjects: 60
Study: 36006505

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (CRT)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Chemotherapy (CT)
Number of subjects: 71
Study: 34962560

Group type: EXPERIMENTAL
Intervention: Internet-based self-management program (n=116)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Usual care (n=113)
Number of subjects: 230
Study: 36244254

Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality (IVR) training
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (15-min 2D video)
Number of subjects: 107
Study: 33902979

Group type: EXPERIMENTAL
Intervention: Conventional method (verbal explanation supported with the BOS leaflet)
Number of subjects: 64

Group type: COMPARATOR
Intervention: 3D animated content based on the BOS leaflet
Number of subjects: 64
Study: 33735884

Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m2 and carboplatin AUC 5 every 3 weeks
Number of subjects: 164

Group type: COMPARATOR
Intervention: Paclitaxel 80 mg/m2 on day 1, day 8, and day 15 with carboplatin AUC 5 every 4 weeks for 4 cycles
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Pemetrexed-carboplatin
Number of subjects: 164

Group type: COMPARATOR
Intervention: Paclitaxel-carboplatin
Number of subjects: 164
Study: 33406480

Group type: EXPERIMENTAL
Intervention: Session Ratings of Perceived Exertion (sRPE) using the CR100 scale
Number of subjects: 59
Study: 32603389

Group type: EXPERIMENTAL
Intervention: CO2 laser ablative fractional resurfacing (AFR) followed by ALA photodynamic therapy (PDT)
Number of subjects: 19

Group type: COMPARATOR
Intervention: ALA photodynamic therapy (PDT) alone
Number of subjects: 19
Study: 34718434

Group type: EXPERIMENTAL
Intervention: Tocilizumab weekly (TCZ QW)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Tocilizumab every-other-week (TCZ Q2W)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study: 33736638

Group type: EXPERIMENTAL
Intervention: NCB-PT® (9 patients)
Number of subjects: 28

Group type: COMPARATOR
Intervention: VA-LCP® (19 patients)
Number of subjects: 28
Study: 32393496

Group type: EXPERIMENTAL
Intervention: 3,600 mg MHAA4549A + OTV
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: 8,400 mg MHAA4549A + OTV
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo + OTV
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: MHAA4549A + OTV
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 166
Study: 34534556

Group type: EXPERIMENTAL
Intervention: Dichoptic digital therapeutic used at home for 1 hour per day, 6 days per week, with full-time glasses wear.
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group continued wearing glasses full-time alone.
Number of subjects: 105
Study: 34155736

Group type: EXPERIMENTAL
Intervention: Unicornuate uterus (UU)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Normal uterus (control)
Number of subjects: 44
Study: 33026749

Group type: EXPERIMENTAL
Intervention: Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% foam plus apremilast
Number of subjects: 28

Group type: COMPARATOR
Intervention: Vehicle foam plus apremilast
Number of subjects: 28
Study: 35688490

Group type: EXPERIMENTAL
Intervention: Micronised progesterone (Utrogestan® 200mg) + transdermal oestradiol (Evorel® Patches 50mcg/day)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate (Provera® 10mg) + transdermal oestradiol (Evorel® Patches 50mcg/day)
Number of subjects: 57
Study: 33472681

Group type: EXPERIMENTAL
Intervention: Convalescent plasma (single infusion) plus standard of care (SOC)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Standard of care (SOC) alone
Number of subjects: 278
Study: 32125903

Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride extended-release capsules (MPH-MLR) 10 mg once daily, with weekly adjustments up to 40 mg.
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride extended-release capsules (MPH-MLR)
Number of subjects: 119
Study: 35266244

Group type: EXPERIMENTAL
Intervention: 10+ hours of sleep (sleep extension)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 8 hours of sleep (control)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Brisk walking (exercise)
Number of subjects: 12
Study: 32031090

Group type: EXPERIMENTAL
Intervention: Diode laser application prior to restoration with Universal Single Bond (Self Etch) and Grandio.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Diode laser application prior to restoration with Universal Single Bond (Total Etch) and Grandio.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group with Universal Single Bond (Self Etch) and Grandio without diode laser application.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group with Universal Single Bond (Total Etch) and Grandio without diode laser application.
Number of subjects: 80
Study: 33268562

Group type: EXPERIMENTAL
Intervention: Ibudilast
Number of subjects: 255

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study: 32507386

Group type: EXPERIMENTAL
Intervention: Single-infusion donor-derived anti-CD19 CAR T cells
Number of subjects: 11
Study: 34321181

Group type: EXPERIMENTAL
Intervention: Polyhexamethylene biguanide discs
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard unmedicated dressings
Number of subjects: 80
Study: 34145052

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study: 35287091

Group type: EXPERIMENTAL
Intervention: Droperidol 5 mg/midazolam 5 mg IM
Number of subjects: 86

Group type: COMPARATOR
Intervention: Haloperidol 5 mg/lorazepam 2 mg IM
Number of subjects: 86
Study: 34270425

Group type: EXPERIMENTAL
Intervention: Global Texture Randomization (GTR)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Local Texture Randomization (LTR)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Consistency between GTR and LTR (CGL)
Number of subjects: 5
Study: 35939501

Group type: EXPERIMENTAL
Intervention: UV-4 hydrochloride (UV-4B) at doses of 3, 10, 30, 90, 180, 360, 720, or 1000 mg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: UV-4 hydrochloride (UV-4B)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 33148955

Group type: EXPERIMENTAL
Intervention: 1-g intravenous (IV) TXA prior to incision (single-dose IV group)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: 1-g IV TXA prior to incision followed by 1-g IV TXA after arthrotomy wound closure (double-dose IV group)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: 1-g IV TXA prior to incision and 1-g intraoperative topical TXA (combined IV and topical group)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: 3 doses totaling 1,950-mg oral TXA (multidose oral group)
Number of subjects: 175
Study: 36115179

Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 144

Group type: COMPARATOR
Intervention: Navigation assistance
Number of subjects: 144

Group type: COMPARATOR
Intervention: Patient-specific instrumentation (PSI)
Number of subjects: 144
Study: 33715251

Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution
Number of subjects: 333

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 333
Study: 32762769

Group type: EXPERIMENTAL
Intervention: Psychological resilience (measured by the Asian Resilience Scale)
Number of subjects: 1743

Group type: EXPERIMENTAL
Intervention: Positive coping style (measured by the Simplified Coping Style Questionnaire)
Number of subjects: 1743

Group type: EXPERIMENTAL
Intervention: Psychological resilience factors (mood control, self-plasticity, coping flexibility)
Number of subjects: 1743

Group type: COMPARATOR
Intervention: Gender and major (Medical vs Non-medical students)
Number of subjects: 1743
Study: 34038318

Group type: EXPERIMENTAL
Intervention: EHRs with P100 filters
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: EHRs with N95 filters
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: PAPRs
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Full-facepiece respirators
Number of subjects: 16
Study: 33198809

Group type: EXPERIMENTAL
Intervention: Radiomics nomogram based on texture parameters and clinicopathological factors
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Radiomics nomogram
Number of subjects: 544
Study: 33726868

Group type: EXPERIMENTAL
Intervention: Virtual multicentre training initiative and remote source data verification audit
Number of subjects: 572
Study: 35120150

Group type: EXPERIMENTAL
Intervention: Formula supplementation (up to 59 milliliters administered daily for 30 days)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Breastfeeding alone (exclusive breastfeeding without supplementation)
Number of subjects: 324
Study: 33610052

Group type: EXPERIMENTAL
Intervention: Peer education model
Number of subjects: 88
Study: 35669367

Group type: EXPERIMENTAL
Intervention: Exercise combined with diet intervention
Number of subjects: 104

Group type: COMPARATOR
Intervention: Exercise and routine nursing (Control)
Number of subjects: 104
Study: 33685740

Group type: EXPERIMENTAL
Intervention: CAD/CAM cutting and drilling guides accompanied with pre‐bent titanium plates (group A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: CAD/CAM splints (group B)
Number of subjects: 50
Study: 32401941

Group type: EXPERIMENTAL
Intervention: Music at 432 Hz (n=15)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Music at 440 Hz (n=15)
Number of subjects: 42

Group type: COMPARATOR
Intervention: No music (Control group, n=12)
Number of subjects: 42
Study: 35819163

Group type: EXPERIMENTAL
Intervention: Ropivacaine combined with dexamethasone (Group D)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ropivacaine only (Group C)
Number of subjects: 60
Study: 34274932

Group type: EXPERIMENTAL
Intervention: CatInfo tool (interactive computer-based tool with detailed audio-visual presentation)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo video (control group)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: CatInfo tool satisfaction
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: CatInfo tool usefulness
Number of subjects: 61
Study: 36222185

Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 6
Study: 33768599

Group type: EXPERIMENTAL
Intervention: GDMT Team intervention
Number of subjects: 118

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 118
Study: 32783421

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection
Number of subjects: 30
Study: 35564709

Group type: EXPERIMENTAL
Intervention: Blueberry juice (60 mL per day for 20 days)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (60 mL per day for 20 days)
Number of subjects: 45
Study: 34528089

Group type: EXPERIMENTAL
Intervention: Suprafascial vancomycin powder
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (no vancomycin powder)
Number of subjects: 34
Study: 34615742

Group type: EXPERIMENTAL
Intervention: Mirror Cross Exercise (MCE)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Kinetic Chain Approach (KCA)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (regular training program)
Number of subjects: 39
Study: 33803802

Group type: EXPERIMENTAL
Intervention: 30 g of oat oil with a high concentration (40%) of polar lipids (PLH)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 30 g of rapeseed oil (RSO)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 30 g of oat oil with a low concentration (4%) of polar lipids (PLL)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No added lipids (NL)
Number of subjects: 20
Study: 33099836

Group type: EXPERIMENTAL
Intervention: Fractional Carbon Dioxide Laser (FCO2)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Fractional Radiofrequency (FRF)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Combination of FCO2 and FRF
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (FRF side)
Number of subjects: 27
Study: 34486480

Group type: EXPERIMENTAL
Intervention: Glaucoma
Number of subjects: 30097

Group type: COMPARATOR
Intervention: Visual impairment (VI), AMD, and cataract
Number of subjects: 30097
Study: 33292886

Group type: EXPERIMENTAL
Intervention: Healthy eating intervention consisting of sessions on breastfeeding (BF) and healthy complementary feeding promotion.
Number of subjects: 323

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided).
Number of subjects: 323
Study: 35616994

Group type: EXPERIMENTAL
Intervention: Web-based intervention
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Telephone intervention
Number of subjects: 458

Group type: COMPARATOR
Intervention: Active control
Number of subjects: 458
Study: 32882447

Group type: EXPERIMENTAL
Intervention: Monthly aflibercept injections (2 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Quarterly aflibercept injections (2 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (monthly and quarterly aflibercept injections)
Number of subjects: 40
Study: 32590809

Group type: EXPERIMENTAL
Intervention: quetiapine plus sulforaphane (SFN)
Number of subjects: 100

Group type: COMPARATOR
Intervention: quetiapine plus placebo
Number of subjects: 100
Study: 36107843

Group type: EXPERIMENTAL
Intervention: OC‐01 0.03 mg BID
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: OC‐01 0.06 mg BID
Number of subjects: 182

Group type: COMPARATOR
Intervention: Vehicle nasal spray BID
Number of subjects: 182
Study: 33251022

Group type: EXPERIMENTAL
Intervention: VHM + ART
Number of subjects: 15

Group type: COMPARATOR
Intervention: ART only
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: VHM + ART and ART only
Number of subjects: 15
Study: 33792961

Group type: EXPERIMENTAL
Intervention: Laser-assisted hyaluronic acid (HA) delivery with ablative fractional carbon dioxide laser (AFXL)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 20
Study: 32204612

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Core stability training
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Core stability training vs. Acupuncture
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Functional capacity measures
Number of subjects: 135
Study: 34238436

Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 1280

Group type: COMPARATOR
Intervention: Drug therapy
Number of subjects: 1280
Study: 33119078

Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy
Number of subjects: 26

Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 26
Study: 33180994

Group type: EXPERIMENTAL
Intervention: Pedometer Intervention (PI)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Self-reported depression symptoms
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Physical activity level
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Psychiatric symptoms
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Health-related quality of life
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Components of the Motivation Volition Process Model
Number of subjects: 400
Study: 32672612

Group type: EXPERIMENTAL
Intervention: 0.1% Nepafenac
Number of subjects: 152

Group type: COMPARATOR
Intervention: 1% Prednisolone Acetate
Number of subjects: 152
Study: 34635804

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT) treatment once a week for four weeks with 3000 impulses each
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo treatment with air-filled microspheres
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 155
Study: 35217003

Group type: EXPERIMENTAL
Intervention: dupilumab 300 mg every 2 weeks for up to 96 weeks
Number of subjects: 187

Group type: COMPARATOR
Intervention: placebo in VENTURE followed by dupilumab in TRAVERSE
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: dupilumab
Number of subjects: 187
Study: 33819216

Group type: EXPERIMENTAL
Intervention: Active isolated stretching (self-assisted) before eccentric exercises
Number of subjects: 60
Study: 35387483

Group type: EXPERIMENTAL
Intervention: Ticagrelor 60 mg BD
Number of subjects: 200

Group type: COMPARATOR
Intervention: Aspirin 100 mg OD
Number of subjects: 200
Study: 33955842

Group type: EXPERIMENTAL
Intervention: Nonfood photography while eating
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Food photography while eating
Number of subjects: 208

Group type: COMPARATOR
Intervention: No phone use
Number of subjects: 208
Study: 32879783

Group type: EXPERIMENTAL
Intervention: Levosulpiride (25 mg orally TID for 7 days)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (lactose pill, orally TID for 7 days)
Number of subjects: 35
Study: 35902936

Group type: EXPERIMENTAL
Intervention: Propolis mouthwash (2.5%)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo mouthwash (normal saline)
Number of subjects: 17
Study: 33756421

Group type: EXPERIMENTAL
Intervention: Carboplatin with pegylated liposomal doxorubicin (CD)
Number of subjects: 976

Group type: COMPARATOR
Intervention: Carboplatin with paclitaxel (CP)
Number of subjects: 976

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 976
Study: 36396451

Group type: EXPERIMENTAL
Intervention: Atogepant 10 mg
Number of subjects: 910

Group type: EXPERIMENTAL
Intervention: Atogepant 30 mg
Number of subjects: 910

Group type: EXPERIMENTAL
Intervention: Atogepant 60 mg
Number of subjects: 910

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 910
Study: 33518350

Group type: EXPERIMENTAL
Intervention: Free range (FR) housing environment
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hy-Line W-36 strain
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hy-Line Brown strain
Number of subjects: 12
Study: 32512353

Group type: EXPERIMENTAL
Intervention: Adjunctive group-based psychosocial intervention (12 weekly sessions and 3 monthly booster sessions)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 68
Study: 36459058

Group type: EXPERIMENTAL
Intervention: Cloth mask
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Surgical mask
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: FFP2 mask
Number of subjects: 40

Group type: COMPARATOR
Intervention: No mask (control)
Number of subjects: 40
Study: 32970235

Group type: EXPERIMENTAL
Intervention: Improved nutrition in the first 1000 days
Number of subjects: 1027

Group type: COMPARATOR
Intervention: Other exposure status (less nutritious supplement or improved nutrition at other ages)
Number of subjects: 1027

Group type: EXPERIMENTAL
Intervention: Other biomarkers
Number of subjects: 1027